Trinity Biotech (TRIB) Total Non-Current Liabilities (2009 - 2025)

Trinity Biotech has disclosed Total Non-Current Liabilities across 17 years of filings, most recently posting $35.9 million for Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $35.9 million, down 66.22% year-over-year; the trailing twelve-month figure through Dec 2025 was $35.9 million (down 66.22% YoY), and the FY2025 annual result was $35.9 million, down 66.22% from the prior year.
• Total Non-Current Liabilities came in at $35.9 million for Q4 2025 at Trinity Biotech, down from $117.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $117.6 million in Q2 2025 to a low of $18.7 million in Q4 2021.
• The 5-year median for Total Non-Current Liabilities is $77.2 million (2022), against an average of $73.3 million.
• Across the five-year window, Total Non-Current Liabilities sank 82.26% in 2021 and surged 310.94% in 2022, its largest moves.
• Trinity Biotech's Total Non-Current Liabilities stood at $18.7 million in 2021, then jumped by 310.94% to $76.9 million in 2022, then declined by 11.17% to $68.3 million in 2023, then soared by 55.64% to $106.4 million in 2024, then tumbled by 66.22% to $35.9 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $35.9 million (Q4 2025), $117.6 million (Q2 2025), and $106.4 million (Q4 2024), per Business Quant data.